CTOs on the Move

Unity Biotechnology

www.unitybiotechnology.com

 
UNITY Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. UNITY`s initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Daren Wilkinson
Senior Director IT Infrastructure Profile
Matthew Park
Senior Director, Information Technology Profile

Funding

Unity Biotechnology raised $116M on 10/27/2016
Unity Biotechnology raised $35M on 08/17/2017
Unity Biotechnology raised $55M on 03/19/2018

Similar Companies

AbSci

AbSci is a global leader in biomanufacturing technologies. The company`s SoluPro™ expression platform achieves ultra-high yields of soluble and active protein products and enables ultra-high efficiency purification processes.

Immunai

Comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes

Pharmacopeia

Pharmacopeia, Inc. is a Cranbury, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vivodyne

Vivodyne accelerates the successful discovery, design, and development of human therapeutics through the convergence of novel biology, robotics, and AI. Our platform enables customers to massively de-risk drug candidates by testing them against functional, lab-grown, human organs and multi-organ systems. We conduct preclinical discovery and clinical development campaigns to generate new therapeutic strategies from these proprietary, physiologically-realistic organs at unprecedented scale, speed, and quality through automation and machine learning. We`re financially backed by some of the most selective and successful venture funds, and several “Top 10” global pharmaceutical innovators have already partnered with us to expand, strengthen, and accelerate their therapeutic pipelines.

Quantapore

Quantapore`s novel, high throughput, massively parallel sequencer will allow rapid, affordable and sensitive sequencing of entire genomes. This desktop system will address the need for efficient sequencing. Revenues will be garnered by seeding units into customer facilities, and then by the sale of consumable cartridges; providing rapid growth as the installed base and customer utilization increases.